Zolis, You are right...it’s frustrating and i
Post# of 36537
(Total Views: 370)
Posted On: 01/17/2021 3:28:40 AM
Re: Zolis_onkel #25500
Zolis,
You are right...it’s frustrating and in my opinion the only thing holding NGIO back domestically is a mainstream partnership. This is why they must tread carefully right now and make sure their data is Uber-solid if they intend to go it alone. It seems like they are doing this. The US healthcare system does not welcome small players even though their tech is superior. They think the large companies can do it better which is sometimes true, but usually fail to realize that the large companies usually just buy the tech from a smaller company then just bring it to market with a different name or a one-off feature.
This is why it was a good decision by Joe and team to work abroad. Also the decision to market as a booster in my opinion is the right choice as its non-threatening to the large companies and actually may make NGIO an attractive licensing partner. Pfizer seems like they may be a good target as well as Astra-Zeneca. Frankly NGIO could license its complete booster all across the landscape and help a lot of people worldwide.
We have much to look forward to, but most importantly the point that hopefully comes across is the Complete Vaccine fills the gaps that the others have and it provides a safe long term solution for either first line protection or as a phase two solution post the initial vaccination period.
You are right...it’s frustrating and in my opinion the only thing holding NGIO back domestically is a mainstream partnership. This is why they must tread carefully right now and make sure their data is Uber-solid if they intend to go it alone. It seems like they are doing this. The US healthcare system does not welcome small players even though their tech is superior. They think the large companies can do it better which is sometimes true, but usually fail to realize that the large companies usually just buy the tech from a smaller company then just bring it to market with a different name or a one-off feature.
This is why it was a good decision by Joe and team to work abroad. Also the decision to market as a booster in my opinion is the right choice as its non-threatening to the large companies and actually may make NGIO an attractive licensing partner. Pfizer seems like they may be a good target as well as Astra-Zeneca. Frankly NGIO could license its complete booster all across the landscape and help a lot of people worldwide.
We have much to look forward to, but most importantly the point that hopefully comes across is the Complete Vaccine fills the gaps that the others have and it provides a safe long term solution for either first line protection or as a phase two solution post the initial vaccination period.
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼